

## CYTOKINES

## IL-17 integrates multiple self-reinforcing, feed-forward mechanisms through the RNA binding protein Arid5a

Nilesh Amatya<sup>1</sup>, Erin E. Childs<sup>1</sup>, J. Agustin Cruz<sup>1</sup>, Felix E. Y. Aggor<sup>1</sup>, Abhishek V. Garg<sup>1</sup>, Andrea J. Berman<sup>2</sup>, Johann E. Gudjonsson<sup>3</sup>, Ulus Atasoy<sup>4</sup>, Sarah L. Gaffen<sup>1\*</sup>Copyright © 2018  
The Authors, some  
rights reserved;  
exclusive licensee  
American Association  
for the Advancement  
of Science. No claim  
to original U.S.  
Government Works

Interleukin-17A (IL-17A) not only stimulates immunity to fungal pathogens but also contributes to autoimmune pathology. IL-17 is only a modest activator of transcription in experimental tissue culture settings. However, IL-17 controls posttranscriptional events that enhance the expression of target mRNAs. Here, we showed that the RNA binding protein (RBP) Arid5a (AT-rich interactive domain-containing protein 5a) integrated multiple IL-17–driven signaling pathways through posttranscriptional control of mRNA. IL-17 induced expression of Arid5a, which was recruited to the adaptor TRAF2. Arid5a stabilized IL-17–induced cytokine transcripts by binding to their 3′ untranslated regions and also counteracted mRNA degradation mediated by the endoribonuclease MCP1P1 (Regnase-1). Arid5a inducibly associated with the eukaryotic translation initiation complex and facilitated the translation of the transcription factors (TFs) IκBζ (*Nfkbiz*) and C/EBPβ (*Cebpb*). These TFs in turn transactivated IL-17–dependent promoters. Together, these data indicated that Arid5a orchestrates a feed-forward amplification loop, which promoted IL-17 signaling by controlling mRNA stability and translation.

## INTRODUCTION

Interleukin-17A (IL-17) is an inflammatory cytokine that is crucial for host defense against microbial pathogens, particularly fungi such as the opportunistic fungus *Candida albicans* (1). IL-17 also drives immunopathology in autoimmune and chronic inflammatory conditions (2). The successful clinical outcomes of drugs blocking IL-17 or its receptor for plaque psoriasis underscore the utility of targeting the IL-17 pathway for therapeutic benefit (2). Therefore, understanding the mechanisms by which IL-17 functions has important clinical implications.

IL-17 is produced by T helper 17 (T<sub>H</sub>17) cells and innate lymphocytes (3) and signals through a dimeric receptor composed of IL-17 receptor A (IL-17RA) and IL-17RC (4). The IL-17R recruits nuclear factor κB (NF-κB) activator 1 (Act1), an adaptor and E3 ubiquitin ligase that is upstream of nearly all known IL-17–dependent activities. Act1 binds to TNF (tumor necrosis factor) receptor–associated factor 6 (TRAF6), which in turn activates the canonical NF-κB pathway and MAPK (mitogen-activated protein kinase) cascades. Together, these pathways drive de novo transcription of IL-17–induced signature genes encoding cytokines [IL-6 and G-CSF (granulocyte-colony stimulation factor)], antimicrobial proteins [lipocalin 2 (Lcn2) and β-defensins], and chemokines (4, 5). Although activation of NF-κB is often considered the major IL-17 signaling event, IL-17 also induces other transcription factors (TFs) including CCAAT/enhancer binding proteins (C/EBPs) and the activator protein 1 (AP1) complex (4). Confirming their importance, DNA binding sites for C/EBP, NF-κB, and AP1 are enriched in the proximal promoter regions of IL-17 target genes (6).

IL-17 signaling in culture systems is typically modest compared to potent inflammatory stimuli such as TNFα (2, 7). Nonetheless, the biological impact of IL-17 is profound because a deficiency in

IL-17 signaling or T<sub>H</sub>17 cells results in protection from autoimmunity [e.g., experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis] and increased susceptibility to pathogens (e.g., the fungus *C. albicans*) (8). One explanation for this paradox is that IL-17 synergizes potently with other inflammatory stimuli commonly found in an inflammatory environment. The molecular basis for synergy is not fully understood but is mediated, in part, through cooperative activation of IL-17–induced TFs that activate downstream genes (9, 10). For example, IL-17 induces IκBζ (NF-κB inhibitor ζ, encoded by *Nfkbiz*) (11), an atypical member of the NF-κB family that facilitates transcription of several IL-17–dependent genes in cooperation with TNFα (12–14). Similarly, C/EBP family members are implicated in functional cooperativity between IL-17 and TNFα (7, 11, 15).

In addition, IL-17 promotes stabilization of mRNA (16). Many IL-17–induced transcripts have adenylate-uridylate-rich elements or other stability-determining sequences in the 3′ untranslated region (3′UTR) (17). IL-17 promotes mRNA stabilization of numerous genes, including *Il6*, C-X-C motif chemokine ligand 1 (*Cxcl1*), and *Cxcl5* among others (16). RNA binding proteins (RBPs) such as Hu-antigen R (HuR) and DEAD-box helicase 3 X-Linked (DDX3X) are recruited to the IL-17R/Act1 complex through the adaptors TRAF2 and TRAF5. HuR binds to and stabilizes *Cxcl1* and *Cxcl5* by competing for 3′UTR occupancy with the RNA decay factor splicing factor 2 (SF2) (18–20). Another IL-17 target gene that influences mRNA stability is the endoribonuclease MCP-1 (monocyte chemoattractant protein-1)–induced protein 1 [MCP1P1, also known as Regnase-1, encoded by the gene zinc finger CCCH-type containing 12A (*Zc3h12a*)] (15, 21). IL-17 induces *Zc3h12a* expression and promotes its mRNA stability through DDX3X (20, 22). MCP1P1 mediates 3′UTR-mediated mRNA decay of *Il6*, *Nfkbiz*, and other transcripts and thus is a feedback inhibitor of IL-17 signaling (22). Although these studies provided insights into the importance of mRNA control in the IL-17 pathway, the full extent to which IL-17 regulates mRNA remains incompletely understood.

Here, we showed that the RBP AT-rich interactive domain-containing protein 5A (Arid5a) promoted IL-17 signaling. IL-17 stimulation of target cells increased the abundance of Arid5a and triggered its recruitment to the adaptor TRAF2. Arid5a promoted the expression

<sup>1</sup>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA. <sup>2</sup>Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA. <sup>3</sup>Department of Dermatology, Taubman Center, University of Michigan, Ann Arbor, MI 48109, USA. <sup>4</sup>Division of Allergy and Immunology, University of Michigan, Ann Arbor, MI 48109, USA.  
\*Corresponding author. Email: sarah.gaffen@pitt.edu

of several IL-17–dependent cytokine mRNA transcripts (*Il6*, *Cxcl1*, and *Cxcl5*) by binding to their 3'UTR sequences, enhancing mRNA stability, and counteracting the negative effects of MCPIP1. However, Arid5a also promoted expression of certain IL-17–dependent genes (e.g., *Lcn2*) without affecting mRNA stability. This observation led us to interrogate the impact of Arid5a on IL-17–induced TFs, specifically C/EBP $\beta$  and I $\kappa$ B $\zeta$ . Arid5a stabilized mRNA encoding *Nfkbiz* but not *Cebpb*. Rather, Arid5a strongly enhanced IL-17–induced translation of C/EBP $\beta$  and I $\kappa$ B $\zeta$  proteins, revealing its potential to control translational circuitry.

## RESULTS

### IL-17 increases Arid5a expression and promotes its association with TRAF2

To identify RBPs that might participate in IL-17 signaling cascades, we screened for IL-17–dependent genes encoding RBPs that were induced during a strongly IL-17–dependent immune response (23), specifically, oropharyngeal candidiasis (OPC). Expression of *Arid5a* was enhanced in the oral mucosa (tongue) of wild-type (WT) mice after oral *C. albicans* infection and was impaired in *Il17ra*<sup>-/-</sup> mice (Fig. 1A). This finding paralleled our observations with another RBP, *Zc3h12a* (encoding MCPIP1), which is induced by IL-17 in the tongue during OPC (22). Similarly, IL-17 stimulated the expression of *Arid5a* in the IL-17–responsive stromal cell line, ST2 (Fig. 1B) (22). IL-17–induced *Arid5a* expression was blocked by an NF- $\kappa$ B inhibitor, suggesting that its expression is NF- $\kappa$ B–dependent (fig. S1A).

Some IL-17–dependent pathways that lead to mRNA stabilization are initiated through Act1, TRAF2, and TRAF5 (18–20). To test the hypothesis that Arid5a uses similar proximal signaling intermediates, we transfected a Flag/Myc-Arid5a construct into human embryonic kidney–293T (HEK293T) cells [commercial antibodies (Abs) against endogenous Arid5a are ineffective for immunoprecipitation (IP)] and co-immunoprecipitated Arid5a and TRAF2. Arid5a did not co-immunoprecipitate with Act1 but did associate with TRAF2 (Fig. 1C and fig. S1B). To determine whether the TRAF2-Arid5a association is IL-17–dependent, we transfected ST2 cells with Flag/Myc-Arid5a, stimulated with IL-17 for 2 hours and lysates subjected to IP with Myc Abs. Endogenous TRAF2 co-immunoprecipitated with Arid5a, and the TRAF2-Arid5a interaction peaked at ~15 to 60 min after IL-17 treatment (Fig. 1D and fig. S2E). Together, these data show that IL-17 enhances Arid5a expression, which inducibly associates with TRAF2.

### Arid5a augments the cellular response to IL-17

To ascertain whether Arid5a affects the response to IL-17, we transfected ST2 cells with pooled small interfering RNAs (siRNAs) against Arid5a (knockdown efficiency was typically 40 to 60%; fig. S1, C and D). Cells were treated with IL-17 for 3 hours, and expression of prototypical IL-17 target genes was assessed. Knockdown of Arid5a suppressed IL-17–mediated induction of *Il6* mRNA and secreted IL-6 protein (Fig. 2A and fig. S3A). Similar results were obtained for other canonical IL-17 target genes, including CXCL1 and CXCL5 (Fig. 2A and fig. S3A). However, not all IL-17–driven genes were detectably regulated by Arid5a, such as *Ccl20* and *Csf2* (Fig. 2A). Together, these data show that Arid5a is required for the expression of a subset of IL-17 target genes.

Because Arid5a associated with TRAF2 (Fig. 1, C and D), we postulated that TRAF2 participates in Arid5a-mediated increased expression of IL-17 target genes. ST2 cells were transfected with siRNAs

against TRAF2 and/or Arid5a (knockdown efficiency was ~60 to 70% for Arid5a and ~70 to 80% for TRAF2; fig. S1E). Silencing of TRAF2 decreased IL-17–induced expression of *Il6*, whereas knockdown of TRAF2 in combination with Arid5a did not reduce expression of *Il6* compared to either alone (Fig. 2B). These data are consistent with a model in which Arid5a and TRAF2 act in the same pathway.

TRAF2 promotes mRNA stabilization in the IL-17 pathway through the RBP HuR (encoded by the *Elavl1* gene) (19). Double knockdown of Arid5a and HuR did not change or only marginally decreased IL-17–induced expression of *Il6* or *Cxcl1* compared to knockdown of Arid5a or HuR alone (fig. S2A). Knockdown efficiency was typically ~60% for Arid5a and >95% for HuR (fig. S2B). These results suggest that Arid5a and HuR are likely to function in the same pathway in IL-17 signal transduction. However, in contrast to Arid5a, IL-17 did not induce expression of HuR (*Elavl1*) mRNA (fig. S2C).

In the IL-17 and other inflammatory signaling pathways, competition among RBPs helps determine the overall amount of target mRNA transcripts (4, 18, 19). IL-17 induces the endoribonuclease MCPIP1, which remains elevated during prolonged stimulation and binds to a similar RNA binding site as Arid5a (22, 24). Because the net effect of IL-17 is to enhance expression of mRNAs that can be inhibited by MCPIP1, e.g., *Il6* or *Lcn2* (Fig. 2C), this paradox suggested that IL-17 augments the activity of RBPs that offset the negative effects of MCPIP1. To determine whether Arid5a might serve in this capacity, we knocked down Arid5a and MCPIP1 together (efficiency, ~80%; fig. S1F) and assessed *Il6* and *Lcn2* expression. As reported, MCPIP1 knockdown enhanced IL-17–induced expression of *Il6* and *Lcn2* mRNA (Fig. 2D) and IL-6 protein (fig. S3B), but knockdown of Arid5a partially offsets the inhibitory effect of MCPIP1 deficiency (Fig. 2D and fig. S3B). Knockdown of Arid5a also suppressed the IL-17–induced abundance of LCN2 protein (fig. S3A). Therefore, Arid5a counteracts the activity of MCPIP1 stimulated by IL-17.


IL-17 increases *Il6* expression both through acting on its proximal promoter and by stabilizing its mRNA transcript (7, 25, 26). However, we saw no impact of Arid5a on IL-6 promoter activation, as co-expression of Arid5a with a luciferase reporter driven by the mouse *Il6* promoter did not increase luciferase activity (fig. S1G). To determine whether Arid5a promoted IL-17–dependent stability of *Il6* mRNA, we transfected ST2 cells with siRNAs against Arid5a and primed with TNF $\alpha$  for 3 hours to induce *Il6* mRNA without activating IL-17 signaling. After the cells were washed and treated with actinomycin D to block further transcription, we assessed the half-life ( $t_{1/2}$ ) of target transcripts over 90 min (longer treatments led to cell toxicity) in the presence or absence of IL-17. As previously reported, IL-17 reduced decay of *Il6* transcripts (26), but *Il6* stabilization was impaired upon Arid5a knockdown (Fig. 2E and fig. S8A). Arid5a similarly stabilized *Cxcl1* and *Cxcl5* transcripts (Fig. 2E and figs. S3C and S8B). When we cotransfected HEK293T cells with Arid5a and a luciferase reporter fused to the *Il6* 3'UTR (27), expression of Arid5a increased luciferase activity (Fig. 2F). Control expression of either Act1 enhanced *Il6* 3'UTR reporter activity, whereas MCPIP1 suppressed activity, as expected (28, 29). Thus, these data suggest that Arid5a stabilizes IL-17 target mRNA transcripts encoding inflammatory cytokines and chemokines through interaction with transcript 3'UTRs.

### Arid5a promotes translation of C/EBP $\beta$ and I $\kappa$ B $\zeta$

Unlike *Il6* transcripts, IL-17 does not alter the mRNA stability of *Lcn2* (6). Moreover, Arid5a knockdown did not increase the half-life of *Lcn2*

mRNA (fig. S3E). Even so, when Flag/Myc-Arid5a was coexpressed with a luciferase reporter driven by the mouse *Lcn2* promoter (6), luciferase activity was significantly increased (Fig. 3A). Because there are no apparent Arid5a recognition sites within the *Lcn2* promoter, these data raised the possibility that Arid5a may transactivate the *Lcn2* promoter indirectly through an IL-17-dependent TF. The *Lcn2* promoter contains a C/EBP binding element required for IL-17-dependent induction (6, 10), and Arid5a failed to activate an *Lcn2* promoter with a C/EBP binding site mutation (Fig. 3A) (6). In response to

IL-17, *Cebpb* expression increased two- to fourfold (Fig. 3B), consistent with prior observations (7, 30–32) and raising the possibility that Arid5a increases *Lcn2* by enhancing C/EBP $\beta$  expression. However, Arid5a knockdown did not impair expression of IL-17-induced *Cebpb* mRNA (Fig. 3C). By Western blot, we confirmed that IL-17 increases the abundance of C/EBP $\beta$  protein isoforms known as LAP (liver-activated protein) and LIP (liver inhibitory protein), which are generated by alternative translation (30). We found that silencing of Arid5a strongly inhibited IL-17-induced expression of all C/EBP $\beta$



**Fig. 1. IL-17 increases the abundance of Arid5a, which inducibly associates with TRAF2.** (A) Quantitative reverse transcription PCR (qRT-PCR) analysis of *Arid5a* mRNA expression in the tongue tissue of WT or *Il17ra*<sup>-/-</sup> mice at 24 hours after oral exposure to phosphate-buffered saline (sham) or *C. albicans* (CAF2-1). Fold change data are means  $\pm$  SEM of at least eight mice per group from two independent experiments. (B) Left: qRT-PCR analysis of *Arid5a* mRNA expression in ST2 cells treated with IL-17 for the indicated times. Fold change data are means  $\pm$  SEM from three independent experiments. Right: Western blot analysis of Arid5a on lysates from ST2 cells treated with IL-17A for 4 hours. Blots are representative of three independent experiments. Quantified band intensity values are means  $\pm$  SEM from all experiments. UT, untreated. (C) Co-immunoprecipitation analysis of Arid5a interaction with TRAF2 in lysates from HEK293T cells transfected with empty vector (EV), Flag/Myc-Arid5a, or TRAF2 and immunoprecipitated for Flag. Blots are representative of two independent experiments (fig. S1B). WCL, whole cell lysate. (D) CoIP analysis of Arid5a interaction with TRAF2 in lysates from ST2 cells transfected with Flag/Myc-Arid5a, treated with IL-17 for the indicated times and immunoprecipitated with Ab against Myc. Blots are representative of three independent experiments (fig. S2E). Quantified band intensity values are means  $\pm$  SEM from all experiments. \* $P$  < 0.05, \*\* $P$  < 0.01, \*\*\* $P$  < 0.001, and \*\*\*\* $P$  < 0.0001 by analysis of variance (ANOVA) with post hoc Tukey's test (A), Dunnett's test (B, left), or paired Student's *t* test (B, right).

**Fig. 2. Arid5a promotes cellular responses to IL-17.**

**(A)** qRT-PCR analysis of the indicated mRNAs in ST2 cells transfected with pooled siRNAs targeting Arid5a (siArid5a) or scrambled control (siControl) and treated with IL-17 for 3 hours. Fold change data are means ± SEM from three independent experiments.


**(B)** qRT-PCR analysis of *Il6* mRNA expression in ST2 cells transfected with pooled siRNAs targeting Arid5a, TRAF2, or scrambled control and treated with IL-17 for 3 hours. Fold change data are means ± SEM from three independent experiments.

**(C)** qRT-PCR analysis of *Il6* or *Lcn2* mRNA expression in ST2 cells treated with IL-17 for the indicated times. Fold change data are means ± SEM from three independent experiments.

**(D)** qRT-PCR analysis of *Il6* or *Lcn2* in ST2 cells transfected with pooled siRNAs targeting Arid5a ± MCPIP1 or scrambled control and treated with IL-17 for 3 hours. Fold change data are means ± SEM from three independent experiments.

**(E)** qRT-PCR analysis of *Il6* or *Cxcl1* mRNA in ST2 cells transfected with pooled siRNAs targeting Arid5a or scrambled control, pretreated with TNF $\alpha$  for 3 hours, and then treated with actinomycin D (ActD) and IL-17 for the indicated times. Remaining mRNAs compared to time = 0 data are means ± SEM representative of three independent experiments.

**(F)** Luciferase (LUC) assay of *Il6* 3'UTR activity in HEK293T cells at 24 hours after transfection with a luciferase reporter and EV, Flag/Myc-Arid5a, Act1-Myc, or MCPIP1 and analyzed after 24 hours. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$  by ANOVA with post hoc Tukey's test (A, B, D, and F) or Dunnett's test (C); half-lives ( $t_{1/2}$ ) were determined using equations that defined decay kinetics as shown by colored lines in the graph, as described (42) (E). n.s., not significant.



Downloaded from <http://stke.sciencemag.org/> on December 5, 2019


protein isoforms (Fig. 3D). However, TRAF2 was dispensable for IL-17–induced expression of C/EBP $\beta$  (fig. S2D). Furthermore, neither IL-17 stimulation nor Arid5a knockdown affected the mRNA stability of *Cebpb* transcripts (fig. S3D). Thus, Arid5a appears to promote C/EBP $\beta$  protein abundance but not mRNA expression.

These data suggested that Arid5a may increase C/EBP $\beta$  translation. Therefore, we used RNA-immunoprecipitation (RIP) assays to deter-

mine whether Arid5a affects the occupancy of *Cebpb* within the eukaryotic eIF4F translation initiation complex (Fig. 3E) (33). Accordingly, ST2 cells were transfected with Arid5a siRNA and treated with IL-17, and lysates were immunoprecipitated with Abs against eIF4G, a scaffolding subunit of eIF4F associated with mRNA undergoing active translation (34). We found that *Cebpb* transcripts were enriched in the eIF4G IP fraction after IL-17 stimulation, consistent with increased

**Fig. 3. Arid5a mediates translation of C/EBPβ mRNA.**

**(A)** Luciferase assay of *Lcn2* proximal promoter activity in HEK293T cells transfected with a luciferase reporter together with EV or Flag/Myc-Arid5a and analyzed after 24 hours. Fold change data are means ± SEM from three to five independent experiments. **(B)** qRT-PCR analysis of *Cebpb* mRNA expression in ST2 cells treated with IL-17 for the indicated times. Fold change data are means ± SEM from three independent experiments. **(C)** qRT-PCR analysis of *Cebpb* mRNA expression in ST2 cells transfected with pooled siRNAs targeting Arid5a or scrambled control and treated with IL-17 for 1 hour. Fold change data are means ± SEM from three independent experiments. **(D)** Western blot analysis of C/EBPβ isoforms (LAP\*, LAP, and LIP) in nuclear extracts from ST2 cells transfected with siRNAs targeting Arid5a or control siRNA and treated with IL-17 for 4 hours. Blots are representative of three independent experiments. Quantified band intensity values are means ± SEM from all experiments. **(E)** RIP assay (left) of *Cebpb* mRNA amount by qRT-PCR analysis on immunoglobulin G (IgG) or eIF4G immunoprecipitates from cytoplasmic extracts of ST2 cells after transfection with siRNAs targeting Arid5a or control siRNA and treatment with IL-17 for 3 hours. Inset: Western blot analysis of eIF4G in cytoplasmic fractions immunoprecipitated with IgG or eIF4G. Data are fold change means ± SEM representative of three independent experiments. **(F)** CoIP analysis of Arid5a interaction with eIF4G in lysates from ST2 cells transfected with Flag/Myc-Arid5a, treated with IL-17 for the indicated times, and immunoprecipitated with Ab against eIF4G. Blots are representative of three independent experiments (fig. S2F). Quantified band intensity values are means ± SEM from all experiments. \**P* < 0.05, \*\**P* < 0.01, and \*\*\*\**P* < 0.0001 by ANOVA with post hoc Tukey's test (A and C to F) or Dunnett's test (B).




translation (Fig. 3E and fig. S7A). Similarly, *Il6* and *Cxcl1* transcripts were also enriched, which was expected because their corresponding proteins are increased in abundance in conditioned media after IL-17 stimulation (figs. S5A and S7C). Moreover, Arid5a knockdown impaired enrichment of *Cebpb*, *Il6*, and *Cxcl1* transcripts in the eIF4F complex, supporting a role for Arid5a in promoting trans-

lation of C/EBPβ and other target proteins. Total *Cebpb* mRNAs in the cytoplasmic lysate used as the input for RIP were not affected by Arid5a knockdown (fig. S5B). To determine whether Arid5a itself interacts with the translation initiation complex, we transfected ST2 cells with Flag/Myc-Arid5a and stimulated these cells with IL-17 for 2 hours. When lysates were immunoprecipitated with Myc Abs, we


**Fig. 4. Arid5a mediates translation of I $\kappa$ B $\zeta$ .**

**(A)** qRT-PCR analysis of *Nfkbiz* mRNA expression in ST2 cells treated with IL-17 for the indicated times. Fold change data are means  $\pm$  SEM from three independent experiments. **(B)** Western blot analysis of I $\kappa$ B $\zeta$  in nuclear extracts from ST2 cells treated with IL-17A for indicated times. Blots are representative of three independent experiments. Quantified band intensity values are means  $\pm$  SEM from all experiments. **(C)** Left: qRT-PCR analysis of *Nfkbiz* mRNA expression in ST2 cells transfected with pooled siRNAs targeting Arid5a or scrambled control and treated with IL-17 for 30 min. Fold change data are means  $\pm$  SEM from two independent experiments. Right: Western blot analysis of I $\kappa$ B $\zeta$  in nuclear extracts from ST2 cells transfected with siRNAs targeting Arid5a or control siRNA and treated with IL-17A for 4 hours. Blots are representative of four independent experiments. **(D)** Left: qRT-PCR analysis of *Nfkbiz* mRNA expression in primary MEFs transfected with pooled siRNAs targeting Arid5a or scrambled control and treated with IL-17 for 24 hours. Blots are representative of three independent experiments. **(E)** Western blot analysis of I $\kappa$ B $\zeta$  and Myc-tagged Arid5a in lysates from HEK293T cells transfected with EV, I $\kappa$ B $\zeta$ , or Flag/Myc-Arid5a. Blots are representative of three independent experiments. Quantified band intensity values are means  $\pm$  SEM from all experiments. **(F)** qRT-PCR analysis of *Nfkbiz* mRNA expression in ST2 cells transfected with pooled siRNAs targeting Arid5a or scrambled control that were pretreated with TNF $\alpha$  for 3 hours and then treated with actinomycin D and IL-17 for the indicated times. Remaining mRNAs compared to time = 0 data are means  $\pm$  SEM representative of two independent experiments. **(G)** RIP assay of *Nfkbiz* mRNA amount by qRT-PCR analysis on IgG or eIF4G immunoprecipitates from cytoplasmic extracts of ST2 cells after transfection with siRNAs targeting Arid5a or control siRNA and treatment with IL-17 for 3 hours. Data are fold change means  $\pm$  SEM representative of three independent experiments. Inset: Western blot analysis of eIF4G in cytoplasmic fractions immunoprecipitated with IgG or eIF4G. \* $P$  < 0.05, \*\* $P$  < 0.01, \*\*\* $P$  < 0.001, and \*\*\*\* $P$  < 0.0001 by ANOVA with post hoc Tukey's test or Dunnett's test (A and B); half-lives ( $t_{1/2}$ ) were assessed as described (42) (E).



found that endogenous eIF4G co-immunoprecipitated with Arid5a in an IL-17-dependent manner (Fig. 3F and fig. S2F). These data indicate that Arid5a promotes IL-17-induced translation of C/EBP $\beta$  by interacting with eIF4F translation initiation complex.

The NF- $\kappa$ B family also mediates responses to IL-17, and the *Lcn2* promoter contains an NF- $\kappa$ B site required for IL-17 activation. This site interacts with I $\kappa$ B $\zeta$  (encoded by *Nfkbiz*), a noncanonical member of the NF- $\kappa$ B family that is induced by IL-17 and cooperates with




**Fig. 5. Arid5a binds directly to target mRNA transcripts.** (A and B) qRT-PCR analysis of mRNAs from ST2 cytoplasmic extracts transfected with Flag/Myc-Arid5a, treated with IL-17 for 3 hours, and subjected to RIP with IgG2a or Myc. Data are fold change means  $\pm$  SEM representative of three independent experiments. (C) In vitro RNA pulldown assay (box) of Arid5a-Myc by Western blot analysis streptavidin bead immunoprecipitates from lysates of Arid5a-Myc transfected HEK293T cells incubated with the indicated in vitro-generated, biotinylated mRNAs. Data are derived from the same blot and are representative of three independent experiments for *Il6* and two independent experiments for *Cxcl1* and *Csf2*. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$  by ANOVA with post hoc Tukey's test.

NF- $\kappa$ B p50 (6, 10, 15). Arid5a did not activate a luciferase construct driven by the *Lcn2* promoter mutated at its NF- $\kappa$ B binding site (Fig. 3A), which suggested that Arid5a may enhance expression of I $\kappa$ B $\zeta$ . We found that IL-17 enhanced expression of I $\kappa$ B $\zeta$  both at mRNA and protein levels (Fig. 4, A and B), consistent with prior reports (15, 22, 35, 36). Arid5a silencing only modestly inhibited IL-17-induced mRNA expression of *Nfkbi* in ST2 cells and had no effect in primary mouse embryonic fibroblasts (MEFs; Fig. 4, C and D). In contrast to *Cebpb* transcripts, Arid5a knockdown impaired IL-17-induced stabilization of *Nfkbi* mRNA (Fig. 4F and fig. S8C). However, Arid5a knockdown reduced IL-17-induced I $\kappa$ B $\zeta$  protein abundance in both ST2 cells and MEFs (Fig. 4, C and D, and fig. S4, A and B). Consistently, we found that coexpression of Arid5a with I $\kappa$ B $\zeta$  in HEK293T cells increased I $\kappa$ B $\zeta$  abundance (Fig. 4E), and TRAF2 was not required for IL-17-induced expression of I $\kappa$ B $\zeta$  (fig. S2D). As with *Cebpb* transcripts, *Nfkbi* mRNA was less abundant in eIF4G RIP fractions after Arid5a knockdown, which suggested that Arid5a promotes *Nfkbi* translation (Fig. 4G and figs. S4B and S7B). Thus, our results showed that Arid5a enhanced both mRNA stability and translation of I $\kappa$ B $\zeta$ . Collectively, these data suggest that Arid5a indirectly stimulates target genes that are activated by the IL-17-inducible TFs C/EBP $\beta$  and I $\kappa$ B $\zeta$ .

### Arid5a binds to the 3'UTR of IL-17-induced mRNAs

To determine whether Arid5a binds directly to target mRNAs, ST2 cells were transfected with Flag/Myc-Arid5a, stimulated with IL-17, and nuclear and cytoplasmic fractions of cell lysates were subjected to RIP with Abs against Myc. We found that the association of *Il6*, *Cxcl1*, *Cxcl5*, *Nfkbi*, and *Cebpb* transcripts with Arid5a was increased in cytoplasmic fractions after IL-17 stimulation (Fig. 5A and fig. S6). These transcripts were not enriched in control or nuclear fractions (fig. S5, C to H), consistent with the fact that posttranscriptional control of mRNA takes place in the cytoplasm (17). In contrast, *Ccl20* and *Csf2* transcripts were associated with Arid5a, which agrees with our earlier results that Arid5a knockdown does not affect IL-17-dependent expression of these genes (Fig. 5B and fig. S6; see also Fig. 2A). Together, our data suggest that Arid5a associates specifically with IL-17-induced, cytoplasmically localized mRNA transcripts.

To verify that Arid5a binds directly to the 3'UTRs of target transcripts, we used an in vitro RNA pulldown assay. Biotinylated transcripts encoding the 3'UTR sequences of *Il6*, *Cxcl1*, and *Csf2* were generated in vitro and incubated with recombinant Flag/Myc-Arid5a derived from transfected HEK293T cells. Biotinylated transcripts were isolated with streptavidin-conjugated beads and precipitates subjected to immunoblotting with Myc Abs (Fig. 5C). Consistent with the earlier RIP data, Arid5a was



**Fig. 6. Arid5a promotes responses to IL-17 in primary MEFs and human KCs.** (A) qRT-PCR analysis of primary MEFs transfected with pooled siRNAs targeting Arid5a or scrambled control and treated with IL-17 for 24 hours. Fold change data are means  $\pm$  SEM from three independent experiments. (B) Enzyme-linked immunosorbent assay (ELISA) analysis of conditioned supernatants from MEFs transfected with pooled siRNAs targeting Arid5a or scrambled control and treated with IL-17 for 24 hours. Fold change data are means  $\pm$  SEM representative of two independent experiments. (C) qRT-PCR analysis of human KC (N/TERT2G) cells transfected with pooled siRNAs targeting Arid5a or scrambled control and treated with IL-17 for 5 hours. Fold change data are means  $\pm$  SEM from three independent experiments. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , and \*\*\*\* $P < 0.0001$  by ANOVA with post hoc Tukey's test.

detected in fractions corresponding to the *Il6* and *Cxcl1* 3'UTR sequences but not with the *Csf2* 3'UTR (Fig. 5C). Thus, Arid5a stabilizes IL-17-induced target mRNAs by binding directly to the 3'UTR.

### Arid5a promotes expression of IL-17 target genes in primary MEFs and human keratinocytes

Although ST2 cells are generally a good reflection of IL-17-dependent events in other cell types, we also assessed Arid5a function by siRNA knockdown in primary murine MEFs and N/TERT2G-immortalized human keratinocytes (KCs) (37). N/TERT2G cells maintain normal KC differentiation patterns and are considered to be a good representation of primary human KCs (38). In MEF cells, Arid5a deficiency also decreased IL-17-induced expression of *Il6*, *Cxcl1*, and *Lcn2* mRNA and IL-6 and CXCL1 protein abundance (Fig. 6, A and B). Similarly, silencing of Arid5a in N/TERT2G cells impaired expression of human *LCN2* and *CXCL1* stimulated by IL-17 (Fig. 6C). Thus, Arid5a promotes IL-17 responses in multiple cells, including primary murine and human cell types.


### DISCUSSION

IL-17 signaling dominantly occurs in epithelial and mesenchymal cell types (39), and thus, IL-17 functions as a bridge between the

immune system and inflamed tissue. The signal transduction mechanisms downstream of IL-17 and related cytokines are still incompletely understood. Here, we identified the RNA binding protein Arid5a as a driver of cellular responses to IL-17 in mouse mesenchymal cells and in human KCs. Arid5a bound directly to the 3'UTR of multiple target mRNAs and stabilized IL-17-induced mRNA transcripts encoding IL-6 and CXC chemokines. These activities are similar to those described for Arid5a in the Toll-like receptor (TLR4) signaling pathway (24, 40). In addition, we observed that Arid5a facilitated the translation of two IL-17-dependent TFs, C/EBP $\beta$  and I $\kappa$ B $\zeta$ , which allowed for increased expression of genes reliant on these TFs such as *Lcn2* (Fig. 7). Thus, in these capacities, Arid5a promotes IL-17-driven immunity.

The IL-17 family is a distinct subclass of cytokines. Accumulating evidence indicates that the mechanisms by which IL-17 mediates mRNA stabilization are not the same as better-studied pathways (25, 26, 41–43). For example, IL-17 does not stabilize target mRNAs through the commonly used RBP tristetraprolin and/or the adaptor TRAF6 (19, 43–45). Rather, RBPs such as HuR, DDX3X, and Act1 serve to stabilize IL-17-dependent transcripts in a pathway initiated by TRAF2 and TRAF5 (19, 20, 28). Typically, the RNA-stabilizing activity of these RBPs is offset by destabilizing RBPs, e.g., SF2 (18, 19), which allows for rapid changes in the accumulation of inflammatory mRNAs in response to cues from





**Fig. 7. Model of Arid5a in the IL-17R signaling pathway.** Upon IL-17 stimulation, Arid5a expression is increased, and this RBP is recruited to TRAF2. Arid5a promotes the mRNA stability of multiple genes, including cytokines and chemokines, and the TF *Nfkbiz* (IkBζ). In addition, Arid5a enhances the translation of *Nfkbiz* and *Cebpb*, TFs that in turn regulate downstream genes such as *Lcn2*, which are not intrinsically unstable. Thus, Arid5a is a central player in the posttranscriptional IL-17 signaling cascade.

IL-17 or other stimuli. In an analogous manner, Arid5a function appeared to be offset by the endoribonuclease, MCP1P1 (Regnase-1), which is also induced by IL-17 and which degrades many of the same IL-17-dependent mRNA transcripts (21, 22). In the setting of lipopolysaccharide signaling in macrophages, Arid5a and MCP1P1 bind to an overlapping RNA binding sequence on the *Il6* 3'UTR (24, 46). Nonetheless, in the IL-17 pathway, not all the targets of Arid5a and MCP1P1 were identical (e.g., *Ccl20*, which was strongly affected by MCP1P1 but not detectably altered by Arid5a). Thus, Arid5a and MCP1P1 appear to be opposing players in an RBP-mediated signaling cascade triggered by IL-17.

There is considerable evidence linking Arid5a to IL-17-induced pathways in vivo. We saw that Arid5a was induced in an IL-17-dependent manner in the oral mucosa during *C. albicans* infections, although a contribution of Arid5a to fungal host defense has not been directly demonstrated. *Arid5a*<sup>-/-</sup> mice are resistant to EAE (24), an IL-17-dependent model of autoimmunity (47). Mice lacking either IL-17A or Arid5a show similar resistance to bleomycin-induced lung injury (48–50). In addition, Arid5a is linked to T<sub>H</sub>17 cell differentiation through stabilization of *Il6*, *Stat3*, and *Ox40* in antigen-presenting cells or T cells (24, 40, 51, 52) and thus may enhance IL-17-dependent

responses by virtue of increasing IL-17 expression in the inflamed environment.

IL-17 acts almost exclusively on nonhematopoietic cells (39), so factors such as Arid5a and MCPIP1 that target both  $T_H17$  cells and IL-17 signaling could potentially function in one or both contexts (21, 22). In this regard, the cell type(s) where Arid5a functions in EAE or bleomycin injury have not been determined; however, in a model of IL-17–driven psoriasis, MCPIP1 acts entirely within the nonhematopoietic compartment (53). More studies will be needed to delineate the specific cell types in which Arid5a (or MCPIP1) contributes to autoimmune responses.

Our data revealed a role for Arid5a in increasing expression of the TFs C/EBP $\beta$  and I $\kappa$ B $\zeta$ , which play vital roles in IL-17–driven disease. For example, *Arid5a*<sup>-/-</sup>, *Cebpb*<sup>-/-</sup>, and *Nfkbiz*<sup>-/-</sup> mice are all refractory to EAE (24, 54, 55), and *Nfkbiz*<sup>-/-</sup> mice are also resistant to imiquimod-induced inflammation, a model representing psoriasis-like IL-17–dependent skin inflammation (35). Once induced, C/EBP $\beta$  and I $\kappa$ B $\zeta$  promote expression of genes encoded by mRNAs that are not themselves intrinsically unstable, such as the canonical IL-17 target gene *Lcn2* (6). IL-17 enhanced *Cebpb* and *Nfkbiz* mRNA, albeit modestly (7, 56), whereas concomitant protein expression of both TFs was profoundly increased. However, the mechanisms underlying translational control of these proteins have been elusive (30, 32, 36, 57). We observed that Arid5a associated with the translation initiation complex and that Arid5a knockdown impaired translation of both C/EBP $\beta$  and I $\kappa$ B $\zeta$ . Although TRAF2 inducibly associated with Arid5a and is implicated in promoting HuR-induced stabilization in the IL-17 pathway (19, 28), TRAF2 was dispensable for promoting translation of these TFs. Consistently, TRAF2 is not found in translationally active polysomes after IL-17 stimulation (19). Accordingly, Arid5a appears to direct mRNA translation and mRNA stabilization by differing mechanisms. Arid5a is highly expressed in the nucleus, but TLR4 signaling induces its translocation to the cytoplasm (58). Although it is not known whether IL-17 similarly alters Arid5a subcellular localization, Arid5a occupancy with its target mRNAs occurred only in cytoplasmic, not in nuclear, extracts. Collectively, these findings show that, by inducing expression of these key TFs, Arid5a amplifies the IL-17–driven signaling program.

Blocking IL-17 is remarkably effective in treating psoriasis and is under evaluation for other autoimmune conditions (59, 60). Hence, defining the molecular basis of IL-17 signal transduction may inform therapeutic strategies for diseases where IL-17 is implicated (61). Exploiting RNA is particularly attractive, given the potential for exquisite specificity in targeting otherwise “undruggable” molecules. There are emerging therapeutic approaches directed at RNA or RBPs (62). For example, oligonucleotide “aptamers” representing an Act1 recognition site in the *Cxcl1* 3'UTR were effective in preclinical models of autoimmunity (28). Arid5a was reported to be a target of the antipsychotic drug chlorpromazine (51), suggesting a possible option for diseases involving IL-17. Hence, gaining a mechanistic understanding of how RNA expression is regulated could lead to rational design of new therapies.

## MATERIALS AND METHODS

### Cell culture

ST2, HEK293T, and MEFs were cultured in  $\alpha$ -minimum essential medium ( $\alpha$ -MEM; Sigma-Aldrich, St. Louis MO) with L-glutamine, antibiotics, and 10% fetal bovine serum (11). N/TERT2G cells were

cultured in KC serum-free media (Gibco) supplemented with bovine pituitary extract (30  $\mu$ g/ml), recombinant human epidermal growth factor (0.2 ng/ml), CaCl<sub>2</sub>, and antibiotics. Murine IL-17, human IL-17, and murine TNF $\alpha$  (PeproTech, Rocky Hill, NJ) were used at 200, 100, and 10 ng/ml, respectively. The I $\kappa$ B kinase inhibitor VII (EMD Millipore, Burlington, MA) and actinomycin D (Sigma-Aldrich, St. Louis, MO) were used at 10  $\mu$ M and 5  $\mu$ g/ml, respectively.

### Mice

Oral candidiasis was performed by sublingual inoculation of *C. albicans* (CAF2-1) for 75 min under anesthesia (23). RNA was prepared from tongue after dissociation on a GentleMACS (Miltenyi Biotec, Cambridge, MA) with M tubes. Mice were age-matched on the C57BL/6 background, and both sexes were used. WT mice were from the Jackson Laboratory (Bar Harbor, ME). *Il17ra*<sup>-/-</sup> mice were from Amgen. Protocols were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and adhered to guidelines in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH).

### siRNA, plasmids, and qPCR

ON-TARGETplus SMARTpool siRNAs targeting Arid5a, HuR, TRAF2, and MCPIP1 were from Dharmacon (Lafayette, CO). For RNA silencing, ST2 cells and MEFs were seeded overnight in antibiotic-free  $\alpha$ -MEM, and N/TERT2G cells were seeded in KC serum-free media (Gibco) with supplements. Transfection was performed 18 hours later with 50 nM siRNAs with DharmaFECT Reagent 1. Culture media were replaced after 24 hours, and IL-17 was administered 24 hours later. Flag/Myc-Arid5a was from OriGene (Rockville, MD). All other constructs were described (6, 22, 27, 63). Transfections of ST2 cells and MEFs were performed with FuGENE HD (Promega, Madison, WI) or CaPO<sub>4</sub> (HEK293T cells). RNA was prepared with RNeasy kits (Qiagen, Valencia, CA). Complementary DNA was synthesized by SuperScript III First Strand Kits (Thermo Fisher Scientific, Waltham MA). Quantitative real-time PCR (qPCR) was performed with the SYBR Green FastMix (Quanta BioSciences, Beverly, MA) and analyzed on an ABI 7300 real-time instrument. Primers were from QuantiTect Primer Assays (Qiagen).

### ELISA, Abs, IP, and luciferase assays

ELISA kits were from eBioscience (Thermo Fisher Scientific). Abs used for Western blots and coIP were Arid5a, FLAG (Sigma-Aldrich),  $\beta$ -actin horseradish peroxidase (HRP),  $\alpha$ -tubulin HRP (Abcam, Cambridge, UK), I $\kappa$ B $\zeta$ , Myc (Cell Signaling, Beverly, MA), C/EBP $\beta$  (BioLegend, San Diego, CA), I $\kappa$ B $\alpha$ , MCPIP1, TRAF2, Act1, and YY1 (Santa Cruz Biotechnology, Santa Cruz, CA). Protein G or protein A beads (Roche) were used to pull down Abs during coIP. Luciferase assays used the Dual-Luciferase Reporter Assay System (Promega) (6).

### RIP and biotinylated RNA pulldown

Cytoplasmic extracts were isolated with polysome lysis buffer for Myc RIP [100 mM KCl, 5 mM MgCl<sub>2</sub>, 10 mM Hepes (pH 7.0), 0.5% NP-40, and 1 mM dithiothreitol (DTT)] with RNase Out (100 U/ml; Invitrogen) or CHAPS lysis buffer for eIF4G RIP [0.3% CHAPS, 40 mM Hepes (pH 7.5), 120 mM NaCl, 1 mM EDTA, 10 mM sodium pyrophosphate, 10 mM  $\beta$ -glycerophosphate, 50 mM NaF, 1.5 mM sodium orthovanadate, and 1 mM DTT], supplemented with protease inhibitor cocktail (Sigma-Aldrich). Nuclear extracts were isolated

as described (64). Lysates were precleared with isotype control Abs (Abcam) and protein G agarose beads (Roche) or protein G-conjugated magnetic dynabeads for eIF4G RIP (Life Technologies) and immunoprecipitated with Myc- or eIF4G Abs (Cell Signaling) (34). Immunoprecipitates were incubated with protein G beads or protein G-conjugated magnetic dynabeads for eIF4G RIP. Total RNA was extracted with acid phenol. For biotinylation, 3'UTR motifs from *Il6*, *Cxcl1*, and *Csf2* (GeneArt, Thermo Fisher Scientific) were subcloned in pCR2.1. RNA was synthesized with biotinylated cytidine 5'-triphosphate (Enzo Life Sciences, Farmingdale, NY) in the TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher Scientific) and mixed with lysates from HEK293T cells transfected with Flag-MycArid5a, followed by streptavidin Dynabeads M-280 (Thermo Fisher Scientific). Fractions were isolated by magnetic separation.

### Statistics

ANOVA with post hoc Tukey's analysis or Student's *t* test was used to assess statistical significance, with *P* < 0.05 considered significant.

### SUPPLEMENTARY MATERIALS

www.sciencesignaling.org/cgi/content/full/11/551/eaat4617/DC1  
 Fig. S1. Arid5a interactions within the IL-17 signaling pathway.  
 Fig. S2. Role of TRAF2 and HuR in Arid5a-mediated IL-17 response.  
 Fig. S3. Arid5a promotes IL-17-induced mRNA stability.  
 Fig. S4. Arid5a promotes IL-17-induced IκBζ expression.  
 Fig. S5. Arid5a promotes IL-17 responses through distinct mechanisms.  
 Fig. S6. Arid5a binds directly to target mRNA transcripts.  
 Fig. S7. Arid5a promotes translation of IL-17-induced mRNAs.  
 Fig. S8. Arid5a promotes mRNA stability of IL-17-induced genes.

### REFERENCES AND NOTES

- H. R. Conti, S. L. Gaffen, IL-17-mediated immunity to the opportunistic fungal pathogen *Candida albicans*. *J. Immunol.* **195**, 780–788 (2015).
- S. L. Gaffen, R. Jain, A. V. Garg, D. J. Cua, The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. *Nat. Rev. Immunol.* **14**, 585–600 (2014).
- D. J. Cua, C. M. Tato, Innate IL-17-producing cells: The sentinels of the immune system. *Nat. Rev. Immunol.* **10**, 479–489 (2010).
- N. Amatya, A. V. Garg, S. L. Gaffen, IL-17 signaling: The Yin and the Yang. *Trends Immunol.* **38**, 310–322 (2017).
- C. Gu, L. Wu, X. Li, IL-17 family: Cytokines, receptors and signaling. *Cytokine* **64**, 477–485 (2013).
- F. Shen, Z. Hu, J. Goswami, S. L. Gaffen, Identification of common transcriptional regulatory elements in interleukin-17 target genes. *J. Biol. Chem.* **281**, 24138–24148 (2006).
- M. J. Ruddy, G. C. Wong, X. K. Liu, H. Yamamoto, S. Kasayama, K. L. Kirkwood, S. L. Gaffen, Functional cooperation between interleukin-17 and tumor necrosis factor-α is mediated by CCAAT/enhancer binding protein family members. *J. Biol. Chem.* **279**, 2559–2567 (2004).
- J. Li, J.-L. Casanova, A. Puel, Mucocutaneous IL-17 immunity in mice and humans: Host defense vs. excessive inflammation. *Mucosal Immunol.* **11**, 581–589 (2017).
- M. J. Ruddy, F. Shen, J. Smith, A. Sharma, S. L. Gaffen, Interleukin-17 regulates expression of the CXCL chemokine LIX/CXCL5 in osteoblasts: Implications for inflammation and neutrophil recruitment. *J. Leukoc. Biol.* **76**, 135–144 (2004).
- J. R. Karlsen, N. Borregaard, J. B. Cowland, Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-α is controlled by IκB-ζ but neither by C/EBP-β nor C/EBP-δ. *J. Biol. Chem.* **285**, 14088–14100 (2010).
- F. Shen, M. J. Ruddy, P. Plamondon, S. L. Gaffen, Cytokines link osteoblasts and inflammation: Microarray analysis of interleukin-17- and TNF-α-induced genes in bone cells. *J. Leukoc. Biol.* **77**, 388–399 (2005).
- R. Murotomoto, T. Hirao, K. Tawa, K. Hirashima, S. Kon, Y. Kitai, T. Matsuda, IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes. *Int. Immunol.* **28**, 443–452 (2016).
- S. U. Sønder, A. Paun, H.-L. Ha, P. F. Johnson, U. Siebenlist, CIKS/Act1-mediated signaling by IL-17 cytokines in context: Implications for how a CIKS gene variant may predispose to psoriasis. *J. Immunol.* **188**, 5906–5914 (2012).
- C. Johansen, T. Bertelsen, C. Ljungberg, M. Mose, L. Iversen, Characterization of TNF-α- and IL-17A-mediated synergistic induction of DEFB4 gene expression in human keratinocytes through IκBζ. *J. Invest. Dermatol.* **136**, 1608–1616 (2016).
- S. U. Sønder, S. Saret, W. Tang, D. E. Sturdevant, S. F. Porcella, U. Siebenlist, IL-17-induced NF-κB activation via CIKS/Act1: Physiologic significance and signaling mechanisms. *J. Biol. Chem.* **286**, 12881–12890 (2011).
- T. Hamilton, M. Novotny, P. J. Pavicic Jr., T. Herjan, J. Hartupee, D. Sun, C. Zhao, S. Datta, Diversity in post-transcriptional control of neutrophil chemoattractant cytokine gene expression. *Cytokine* **52**, 116–122 (2010).
- P. Anderson, Post-transcriptional control of cytokine production. *Nat. Immunol.* **9**, 353–359 (2008).
- D. Sun, M. Novotny, K. Bulek, C. Liu, X. Li, T. Hamilton, Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing regulatory factor SF2 (ASF). *Nat. Immunol.* **12**, 853–860 (2011).
- T. Herjan, P. Yao, W. Qian, X. Li, C. Liu, K. Bulek, D. Sun, W.-P. Yang, J. Zhu, A. He, J. A. Carman, S. C. Erzurum, H. D. Lipsitz, P. L. Fox, T. A. Hamilton, X. Li, HuR is required for IL-17-induced Act1-mediated CXCL1 and CXCL5 mRNA stabilization. *J. Immunol.* **191**, 640–649 (2013).
- D. Somma, P. Mastrovito, M. Grieco, A. Lavorgna, A. Pignalosa, L. Formisano, A. M. Salzano, A. Scaloni, F. Pacifico, U. Siebenlist, A. Leonardi, CIKS/DDX3X interaction controls the stability of the Zc3h12a mRNA induced by IL-17. *J. Immunol.* **194**, 3286–3294 (2015).
- K. M. Jeltsch, D. Hu, S. Brenner, J. Zöller, G. A. Heinz, D. Nagel, K. U. Vogel, N. Rehage, S. C. Warth, S. L. Edelmann, R. Gloury, N. Martin, C. Lohs, M. Lech, J. E. Stehlein, A. Geerlof, E. Kremmer, A. Weber, H.-J. Anders, I. Schmitz, M. Schmidt-Supprian, M. Fu, H. Holtmann, D. Krappmann, J. Ruland, A. Kallies, M. Heikenwalder, V. Heissmeyer, Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T<sub>H</sub>17 differentiation. *Nat. Immunol.* **15**, 1079–1089 (2014).
- A. V. Garg, N. Amatya, K. Chen, J. A. Cruz, P. Grover, N. Whibley, H. R. Conti, G. Hernandez Mir, T. Sirakova, E. C. Childs, T. E. Smithgall, P. S. Biswas, J. K. Kolls, M. J. McGeachy, P. E. Kolattukudy, S. L. Gaffen, MCP1P1 endoribonuclease activity negatively regulates interleukin-17-mediated signaling and inflammation. *Immunity* **43**, 475–487 (2015).
- H. Conti, F. Shen, N. Nayyar, E. Stocum, J. N. Sun, M. J. Lindemann, A. W. Ho, J. H. Hai, J. J. Yu, J. W. Jung, S. G. Filler, P. Masso-Welch, M. Edgerton, S. L. Gaffen, Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. *J. Exp. Med.* **206**, 299–311 (2009).
- K. Masuda, B. Ripley, R. Nishimura, T. Mino, O. Takeuchi, G. Shioi, H. Kiyonari, T. Kishimoto, Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 9409–9414 (2013).
- M. Shimada, A. Andoh, K. Hata, K. Tadaki, Y. Araki, Y. Fujiyama, T. Bamba, IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. *J. Immunol.* **168**, 861–868 (2002).
- S. Hennessy, C. K. Johnson, Q. Ge, C. L. Armour, J. M. Hughes, A. J. Ammit, IL-17A augments TNF-α-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability. *J. Allergy Clin. Immunol.* **114**, 958–964 (2004).
- W. Zhao, M. Liu, K. L. Kirkwood, p38α stabilizes interleukin-6 mRNA via multiple AU-rich elements. *J. Biol. Chem.* **283**, 1778–1785 (2008).
- T. Herjan, L. Hong, J. Bubenik, K. Bulek, W. Qian, C. Liu, X. Li, X. Chen, H. Yang, S. Ouyang, H. Zhou, J. Zhao, K. Vasu, E. Cockman, M. Aronica, K. A. Sosingh, D. D. Licatalosi, J. Qin, P. L. Fox, T. A. Hamilton, D. Driscoll, X. Li, IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling. *Nat. Immunol.* **19**, 354–365 (2018).
- K. Matsushita, O. Takeuchi, D. M. Standley, Y. Kumagai, T. Kawagoe, T. Miyake, T. Satoh, H. Kato, T. Tsujimura, H. Nakamura, S. Akira, Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. *Nature* **458**, 1185–1190 (2009).
- A. Maitra, F. Shen, W. Hanel, K. Mossman, J. Tocker, D. Swart, S. L. Gaffen, Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 7506–7511 (2007).
- D. M. Cortez, M. D. Feldman, S. Mummid, A. J. Valente, B. Steffensen, M. Vincenti, J. L. Barnes, B. Chandrasekar, IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-β, NF-κB, and AP-1 activation. *Am. J. Physiol. Heart Circ. Physiol.* **293**, H3356–H3365 (2007).
- T. Maekawa, K. Hosur, T. Abe, A. Kantarci, A. Ziogas, B. Wang, T. E. Van Dyke, T. Chavakis, G. Hajishengallis, Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway. *Nat. Commun.* **6**, 8272 (2015).
- P. Kafasla, A. Skliris, D. L. Kontoyiannis, Post-transcriptional coordination of immunological responses by RNA-binding proteins. *Nat. Immunol.* **15**, 492–502 (2014).
- R. M. Lahr, B. D. Fonseca, G. E. Ciotti, H. A. Al-Ashtal, J. J. Jia, M. R. Niklaus, S. P. Blagden, T. Alain, A. J. Berman, La-related protein 1 (LAR1P1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs. *eLife* **6**, e24146 (2017).

35. C. Johansen, M. Mose, P. Omnen, T. Bertelsen, H. Vinter, S. Hailfinger, S. Lorscheid, K. Schulze-Osthoff, L. Iversen, IκBζ is a key driver in the development of psoriasis. *Proc. Natl. Acad. Sci. U.S.A.* **112**, E5825–E5833 (2015).
36. S. Dhamija, R. Winzen, A. Doerrie, G. Behrens, N. Kuehne, C. Schauerte, E. Neumann, O. Dittrich-Breiholz, M. Kracht, H. Holtmann, Interleukin-17 (IL-17) and IL-1 activate translation of overlapping sets of mRNAs, including that of the negative regulator of inflammation, MCP1P1. *J. Biol. Chem.* **288**, 19250–19259 (2013).
37. M. A. Dickson, W. C. Hahn, Y. Ino, V. Ronfard, J. Y. Wu, R. A. Weinberg, D. N. Louis, F. P. Li, J. G. Rheinwald, Human keratinocytes that express hTERT and also bypass a p16<sup>INK4a</sup>-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. *Mol. Cell. Biol.* **20**, 1436–1447 (2000).
38. J. P. H. Smits, H. Niehues, G. Rikken, I. M. J. J. van Vlijmen-Willems, G. W. H. J. F. van de Zande, P. L. J. M. Zeeuwen, J. Schalkwijk, E. H. van den Bogaard, Immortalized N/TERT keratinocytes as an alternative cell source in 3D human epidermal models. *Sci. Rep.* **7**, 11838 (2017).
39. Y. Iwakura, H. Ishigame, S. Saijo, S. Nakae, Functional specialization of interleukin-17 family members. *Immunity* **34**, 149–162 (2011).
40. K. K. Nyati, K. Masuda, M. M. Zaman, P. K. Dubey, D. Millrine, J. P. Chalise, M. Higa, S. Li, D. M. Standley, K. Saito, H. Hanieh, T. Kishimoto, TLR4-induced NF-κB and MAPK signaling regulate the IL-6 mRNA stabilizing protein Arid5a. *Nucleic Acids Res.* **45**, 2687–2703 (2017).
41. W. H. Faour, A. Mancini, Q. W. He, J. A. Di Battista, T-cell-derived interleukin-17 regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-activated protein kinase cascade: Role of distal sequences in the 3'-untranslated region of COX-2 mRNA. *J. Biol. Chem.* **278**, 26897–26907 (2003).
42. J. Hartupée, C. Liu, M. Novotny, X. Li, T. Hamilton, IL-17 enhances chemokine gene expression through mRNA stabilization. *J. Immunol.* **179**, 4135–4141 (2007).
43. S. Datta, M. Novotny, P. G. Pavicic Jr., C. Zhao, T. Herjan, J. Hartupée, T. Hamilton, IL-17 regulates CXCL1 mRNA stability via an AUUUA/tristetraprolin-independent sequence. *J. Immunol.* **184**, 1484–1491 (2010).
44. J. Hartupée, C. Liu, M. Novotny, D. Sun, X. Li, T. A. Hamilton, IL-17 signaling for mRNA stabilization does not require TNF receptor-associated factor 6. *J. Immunol.* **182**, 1660–1666 (2009).
45. K. Bulek, C. Liu, S. Swaidani, L. Wang, R. C. Page, M. F. Gulen, T. Herjan, A. Abbadi, W. Qian, D. Sun, M. Lauer, V. Hascall, S. Misra, M. R. Chance, M. Aronica, T. Hamilton, X. Li, The inducible kinase IKK1 is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. *Nat. Immunol.* **12**, 844–852 (2011).
46. T. Mino, Y. Murakawa, A. Fukao, A. Vandebon, H. H. Wessels, D. Ori, T. Uehata, S. Tartey, S. Akira, Y. Suzuki, C. G. Vinuesa, U. Ohler, D. M. Standley, M. Landthaler, T. Fujiwara, O. Takeuchi, Regnase-1 and Roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms. *Cell* **161**, 1058–1073 (2015).
47. C. L. Langrish, Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, D. J. Cua, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. *J. Exp. Med.* **201**, 233–240 (2005).
48. P. K. Dubey, K. Masuda, K. K. Nyati, M. Mahabub-Uz Zaman, J. P. Chalise, D. Millrine, W. Kai, B. Ripley, T. Kishimoto, Arid5a-deficient mice are highly resistant to bleomycin-induced lung injury. *Int. Immunol.* **29**, 79–85 (2017).
49. E. Cipolla, A. J. Fisher, H. Gu, E. A. Mickler, M. Agarwal, C. A. Wilke, K. K. Kim, B. B. Moore, R. Vittal, IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis. *FASEB J.* **31**, 5543–5556 (2017).
50. M. S. Wilson, S. K. Madala, T. R. Ramalingam, B. R. Gochoicu, I. O. Rosas, A. W. Cheever, T. A. Wynn, Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. *J. Exp. Med.* **207**, 535–552 (2010).
51. K. Masuda, B. Ripley, K. Kumar Nyati, P. Kumar Dubey, M. Mahabub-Uz Zaman, H. Hanieh, M. Higa, K. Yamashita, D. M. Standley, T. Mashima, M. Katahira, T. Okamoto, Y. Matsuuura, O. Takeuchi, T. Kishimoto, Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA. *J. Exp. Med.* **213**, 605–619 (2016).
52. H. Hanieh, K. Masuda, H. Metwally, J. P. Chalise, M. Mohamed, K. K. Nyati, D. M. Standley, S. Li, M. Higa, M. M. Zaman, T. Kishimoto, Arid5a stabilizes OX40 mRNA in murine CD4<sup>+</sup> T cells by recognizing a stem-loop structure in its 3'UTR. *Eur. J. Immunol.* **48**, 593–604 (2017).
53. L. Minon, J. E. Gudjonsson, E. E. Childs, N. Amatya, X. Xing, A. H. Verma, B. M. Coleman, A. Garg, M. Killeen, A. Mathers, N. L. Ward, S. L. Gaffen, MCP1P1/regnase-1 restricts IL-17A- and IL-17C-dependent skin inflammation. *J. Immunol.* **198**, 767–775 (2017).
54. I. Screpanti, L. Romani, P. Musiani, A. Modesti, E. Fattori, D. Lazzaro, C. Sellitto, S. Scarpa, D. Bellavia, G. Lattanzio, Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. *EMBO J.* **14**, 1932–1941 (1995).
55. K. Okamoto, Y. Iwai, M. Oh-hora, M. Yamamoto, T. Morio, K. Aoki, K. Ohya, A. M. Jetten, S. Akira, T. Muta, H. Takayanagi, IκBζ regulates T<sub>H</sub>17 development by cooperating with ROR nuclear receptors. *Nature* **464**, 1381–1385 (2010).
56. R. Onishi, S. L. Gaffen, IL-17 and its target genes: Mechanisms of IL-17 function in disease. *Immunology* **129**, 311–321 (2010).
57. D. N. Patel, C. A. King, S. R. Bailey, J. W. Holt, K. Venkatachalam, A. Agrawal, A. J. Valente, B. Chandrasekar, Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-κB and C/EBPβ activation. *J. Biol. Chem.* **282**, 27229–27238 (2007).
58. M. Higa, M. Oka, Y. Fujihara, K. Masuda, Y. Yoneda, T. Kishimoto, Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a. *Proc. Natl. Acad. Sci. U.S.A.* **115**, E1214–E1220 (2018).
59. C. Leonardi, R. Matheson, C. Zachariae, G. Cameron, L. Li, E. Edson-Heredia, D. Braun, S. Banerjee, Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. *N. Engl. J. Med.* **366**, 1190–1199 (2012).
60. K. A. Papp, C. Leonardi, A. Menter, J.-P. Ortonne, J. G. Krueger, G. Kricorian, G. Aras, J. Li, C. B. Russell, E. H. Z. Thompson, S. Baumgartner, Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. *N. Engl. J. Med.* **366**, 1181–1189 (2012).
61. A. Ernst, G. Avvakumov, J. Tong, Y. Fan, Y. Zhao, P. Alberts, A. Persaud, J. R. Walker, A.-M. Neculai, D. Neculai, A. Vorobov, P. Garg, L. Beatty, P.-K. Chan, Y.-C. Juang, M.-C. Landry, C. Yeh, E. Zeqiraj, K. Karamboulas, A. Allali-Hassani, M. Vedadi, M. Tyers, J. Moffat, F. Sicheri, L. Pelletier, D. Durocher, B. Raught, D. Rotin, J. Yang, M. F. Moran, S. Dhe-Paganon, S. S. Sidhu, A strategy for modulation of enzymes in the ubiquitin system. *Science* **339**, 590–595 (2013).
62. S. T. Croke, J. L. Witztum, C. F. Bennett, B. F. Baker, RNA-targeted therapeutics. *Cell Metab.* **27**, 714–739 (2018).
63. O. Eickelberg, A. Pansky, R. Mussmann, M. Bihl, M. Tamm, P. Hildebrand, A. P. Perruchoud, M. Roth, Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. *J. Biol. Chem.* **274**, 12933–12938 (1999).
64. S. L. Gaffen, S. Y. Lai, W. Xu, F. Gouilleux, B. Groner, M. A. Goldsmith, W. C. Greene, Signaling through the IL-2R b chain activates a STAT-5-like DNA binding activity. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 7192–7196 (1995).

**Acknowledgments:** We thank Amgen for *Il17ra*<sup>-/-</sup> mice. We acknowledge the valuable advice of B. Fonseca, Children's Hospital of Eastern Ontario Research Institute. We also thank K. Kirkwood (University at Buffalo, SUNY, Buffalo, NY) for the IL-6 3'UTR vector. The *Nfkbiz* plasmid was from U. Siebenlist (NIH, Bethesda, MD). We thank P. Biswas, L. Zhu, and L. Kane (University of Pittsburgh, Pittsburgh, PA) for helpful suggestions and critical reading. **Funding:** NIH supported S.L.G. (AI107825, DE022550, DE023815, and AI128991), A.J.B. (GM116889), U.A. (AI080870), and J.E.G. (AI103325, AR069071). A.J.B. is also supported in part by RSG-17-197-01-RMC from the American Cancer Society. **Author contributions:** N.A., E.E.C., J.A.C., F.E.Y.A., and A.V.G. performed experiments. N.A. and S.L.G. wrote the manuscript with input from all authors. U.A., J.E.G., and A.J.B. provided essential intellectual input and reagents. **Competing interests:** S.L.G. consults for Novartis, Janssen, and Eli Lilly. J.E.G. has research grants from Sun Pharma and AbbVie and is on an advisory board for Novartis. All other authors declare that they have no other competing interests. **Data and materials availability:** The IL-17RA<sup>-/-</sup> mice required a material transfer agreement from Amgen to obtain. All other data needed to evaluate the conclusions in the paper are present in the paper or the Supplementary Materials.

Submitted 1 March 2018

Accepted 7 September 2018

Published 9 October 2018

10.1126/scisignal.aat4617

**Citation:** N. Amatya, E. E. Childs, J. A. Cruz, F. E. Y. Aggor, A. V. Garg, A. J. Berman, J. E. Gudjonsson, U. Ataso, S. L. Gaffen, IL-17 integrates multiple self-reinforcing, feed-forward mechanisms through the RNA binding protein Arid5a. *Sci. Signal.* **11**, eaat4617 (2018).

## IL-17 integrates multiple self-reinforcing, feed-forward mechanisms through the RNA binding protein Arid5a

Nilesh Amatya, Erin E. Childs, J. Agustin Cruz, Felix E. Y. Aggor, Abhishek V. Garg, Andrea J. Berman, Johann E. Gudjonsson, Ulus Atasoy and Sarah L. Gaffen

*Sci. Signal.* **11** (551), eaat4617.  
DOI: 10.1126/scisignal.aat4617

### Stabilizing the IL-17 response

The inflammatory cytokine IL-17 can stimulate both antifungal host defense and autoimmunity by promoting the stability of target mRNAs (see the Focus by Puel and Casanova). Amatya *et al.* found that IL-17 increased the abundance of the RNA binding protein Arid5a in mouse cells. Loss of Arid5a decreased the cellular response to IL-17 by reducing the mRNA stability of a selection of IL-17–stimulated transcripts. For others, Arid5a instead interacted with the translation initiation factor eIF4G to augment their translation. Thus, Arid5a uses multiple posttranscriptional mechanisms to enhance IL-17 signaling.

ARTICLE TOOLS	<a href="http://stke.sciencemag.org/content/11/551/eaat4617">http://stke.sciencemag.org/content/11/551/eaat4617</a>
SUPPLEMENTARY MATERIALS	<a href="http://stke.sciencemag.org/content/suppl/2018/10/04/11.551.eaat4617.DC1">http://stke.sciencemag.org/content/suppl/2018/10/04/11.551.eaat4617.DC1</a>
RELATED CONTENT	<a href="http://stke.sciencemag.org/content/sigtrans/11/551/eaau8876.full">http://stke.sciencemag.org/content/sigtrans/11/551/eaau8876.full</a> <a href="http://stke.sciencemag.org/content/sigtrans/11/538/eaar3083.full">http://stke.sciencemag.org/content/sigtrans/11/538/eaar3083.full</a> <a href="http://stke.sciencemag.org/content/sigtrans/11/545/eaar2125.full">http://stke.sciencemag.org/content/sigtrans/11/545/eaar2125.full</a> <a href="http://science.sciencemag.org/content/sci/332/6025/65.full">http://science.sciencemag.org/content/sci/332/6025/65.full</a> <a href="http://stke.sciencemag.org/content/sigtrans/12/571/eaau2216.full">http://stke.sciencemag.org/content/sigtrans/12/571/eaau2216.full</a> <a href="http://immunology.sciencemag.org/content/immunology/2/17/eaam8834.full">http://immunology.sciencemag.org/content/immunology/2/17/eaam8834.full</a>
REFERENCES	This article cites 64 articles, 29 of which you can access for free <a href="http://stke.sciencemag.org/content/11/551/eaat4617#BIBL">http://stke.sciencemag.org/content/11/551/eaat4617#BIBL</a>
PERMISSIONS	<a href="http://www.sciencemag.org/help/reprints-and-permissions">http://www.sciencemag.org/help/reprints-and-permissions</a>

Use of this article is subject to the [Terms of Service](#)

*Science Signaling* (ISSN 1937-9145) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Signaling* is a registered trademark of AAAS.

Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works